Priority review was based on results from the Phase IIb SunRISe-1 trial, which showed that patients treated with TAR-200 for ...

Preclinical study shows oral PL7737 agonist outperforms tirzepatide alone in rodent models, supporting Palatin’s plans for ...

Sun Pharmaceutical Industries, announced its release of Leqselvi in the U.S. earlier this week. Leqselvi™ is currently ...

A proactive strategy that promotes U.S. pharmaceutical manufacturing is a crucial pillar within a resilient and diversified ...

The OUTREACH Study – Demonstrating that CAR-T therapies can be effectively administered in community cancer settings: In the ...

A Harvard Business School Healthcare Alumni Association Q&A with Dr. Henry A. McKinnell, former Chairman and CEO of Pfizer.

Boehringer Ingelheim, one of the industry leading investors in research and development in innovative life expectancy ...

Industry experts react to the developer’s role in preparing for value-based contracting, acknowledging that innovative agreements can support access when evidence is still maturing.

Marcel Botha discusses whether AI can truly be used to replace laid off human workers at FDA.

Approval of Kerendia was based on results from the Phase III FINEARTS-HF trial, which demonstrated statistically significant ...

Corina Dutcus, SVP, oncology global clinical development lead, Eisai, highlights how long-term LEAP-002 data provides critical reassurance around Lenvima’s durability and safety in treating ...

Willis Chandler is the new president and CEO of Knipper Health. The news came alongside the announcement that Frazier ...